SENS Research Foundation
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
Founding history, funding figures, and the 2024 merger are well documented through the organization's own announcements and independent longevity press, but the core SENS framework itself remains regarded by most mainstream biogerontologists as a speculative long-range research program rather than an established, clinically validated approach.
Reference only. Not medical advice.
SENS Research Foundation was built around Aubrey de Grey's Strategies for Engineered Negligible Senescence framework, which divides the biological damage of aging into seven categories, including cell loss, extracellular junk such as amyloid, intracellular junk, mutations in the nuclear and mitochondrial genome, and cell senescence, and argues that periodically repairing this damage at the molecular and cellular level could prevent age-related disease regardless of its root causes. Rather than running one centralized lab, the foundation historically funded a distributed portfolio of academic research groups worldwide, maintained its own Research Center in Mountain View, California, ran a postdoctoral and PhD-summer-scholar training pipeline, hosted annual scientific conferences on rejuvenation biotechnology, and seeded early stage spinoff companies, including in senescent-cell science and mitochondrial repair, such as Underdog Pharmaceuticals and OncoSenX. Its budget has been modest relative to biotech industry norms, at several million dollars a year through most of its history, funded by individual donors, a handful of large gifts including de Grey's own inheritance, and crowdfunding campaigns that supported specific early stage projects. When SENS was first proposed in the early 2000s, mainstream biogerontologists were broadly skeptical, and a 2005 critique in EMBO Reports and a related debate in MIT Technology Review characterized several of its proposed interventions as speculative or premature given the state of the science at the time. Over the following two decades some SENS-adjacent research directions, notably senolytics targeting senescent cells and approaches to clearing protein aggregates, moved into mainstream geroscience and attracted independent academic and industry investment, which softened some of the earlier skepticism even as specific SENS proposals such as engineered negligible senescence as a near term clinical strategy remain regarded by most aging researchers as long range and unproven. In 2024 the organization merged with Lifespan.io to form Lifespan Research Institute, folding SENS-style damage repair research into a combined research and public education nonprofit, meaning the SENS Research Foundation name is now historical even as its research programs and Mountain View facility continue under the new entity.
SENS Research Foundation was built around Aubrey de Grey's Strategies for Engineered Negligible Senescence framework, which divides the biological damage of aging into seven categories.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Founded in 2009 by biogerontologist Aubrey de Grey and colleagues as a nonprofit spinoff of the earlier Methuselah Foundation, which de Grey had co-founded in 2003. In 2011 de Grey directed roughly 13 million dollars of a personal inheritance into the foundation, roughly doubling its annual budget, and the organization later raised more than 20 million dollars through cryptocurrency donations between 2017 and 2021. In April 2024 SENS Research Foundation announced a merger with the advocacy and journalism outlet Lifespan.io, completed in October 2024, forming a combined nonprofit called Lifespan Research Institute that carries forward SENS-style research alongside public outreach.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about SENS Research Foundation. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
- What people take it for. We have not catalogued the claims made for it.